Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13332998 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4 | |
| SCHEMBL220803 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4 | |
| SCHEMBL222666 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4 | |
| SCHEMBL222742 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4 | |
| SCHEMBL219968 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4 | |
| SCHEMBL222740 | 1.00 | HRH3 (0.57) | HRH3KCNH2CYP3A4 | |
| SCHEMBL2634787 | 0.92 | GAA (0.49) | HRH3KCNH2CYP3A4 | |
| SCHEMBL2634784 | 0.92 | GAA (0.49) | HRH3KCNH2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL3474094 | 0.89 | HRH3 (0.56) | HRH3KCNH2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL2987961 | 0.89 | HRH3 (0.56) | HRH3KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252824-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-08-28 | — | — | US | claimed |
| US-8222290-B2 | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof | SANOFI (FR) | 2012-07-17 | — | — | US | claimed |
| EP-2215058-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-11-23 | — | — | EP | claimed |
| EP-2212283-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | claimed |
| EP-2212283-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | claimed |
| US-8618159-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-8252824-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-08-28 | — | — | US | disclosed |
| WO-2009052068-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052068-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | HRH3 1/4885KCNH2 1508/4885CYP3A4 672/4885 |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | HRH3, HRH4, UTS2R | HRH3 1/4885KCNH2 1819/4885CYP3A4 737/4885 |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 1947/4885CYP3A4 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.